| Total: $759.14 | ||||
Company |
Type Of |
Number Of |
Amount |
Investors; Placement Agents; Details |
AEterna |
Sale of stock in subsidiary |
3.485S |
C$55.1 ($48.4) |
AEterna sold nearly 3.5M shares of subsidiary Atrium Biotechnologies Inc. at C$15.80 each; AEterna now has about 11M Atrium shares, a stake of about 36.1% (10/18) |
Accentia Bio- |
Convertible debenture financing |
N/A |
$25 |
The four-year, 8% debenture provides for the conversion into stock at $2.60 per share; warrants representing 35% of the stock are convertible into shares at $2.75 each; Rodman & Renshaw LLC was placement agent (10/2) |
Acorda |
Private placement of stock |
3.23S |
$31.5 |
The shares were sold at $9.75 each to a limited number of accredited investors (10/4) |
Amarin Corp. plc (UK; AMRN) |
Registered direct offering |
9S |
$18.7 |
The registered shares were sold to new and existing investors at $2.09 each, a discount of 15% to the closing price of its ADSs on Oct. 18 (10/19) |
Antigenics |
Private placement of convertible notes |
N/A |
$25 |
The five-year, 8% notes are convertible into common stock at $3.50 per share; they also can be converted into a 30% interest in Antigenics' QS-21 and AG-707 programs (10/31) |
Ariad |
Private placement of stock |
3.11S |
$14.5 |
The shares were sold from a shelf registration at $4.65 in a deal underwritten by Credit Suisse Securities LLC, which has an option to purchase up to 466,942 additional shares to cover overallotments (10/20) |
Biovitrum AB |
Warrants exercise |
0.623S |
SEK36.8 ($5) |
Investors exercised warrants to purchase about 0.623M shares (10/10 and 10/12) |
Callisto |
Private placement of convertible stock and warrants |
0.105S and 1.4W |
$1.05 |
The company sold 105,000 Series A convertible shares, and 1.4M five-year warrants exercisable at $0.75 per share (10/27) |
Chromos |
Bridge loan |
N/A |
C$2 ($1.77) |
The bridge loan was provided by a syndicate that included Pender NDI Life Sciences Inc., Pender Growth Fund Inc., NeuroDiscovery Ltd. Partnership and Rix Professional Medical Corp. (10/20) |
CollaGenex |
Credit facility |
N/A |
N/A |
CollaGenex expanded its line of credit to $10M from $5M under a loan modification agreement with SVB Silicon Valley Bank; any borrowing would be at the prime rate (10/11) |
Critical |
Private placement of stock and warrants |
7.456S and 3.728W |
$20 |
The securities were sold to institutional investors; the five-year warrants are exercisable at $2.62 per share; Lazard Capital Markets LLC was placement agent (10/27) |
Encysive |
Equity financing commitment |
N/A |
N/A |
Azimuth Opportunity Ltd. committed to buy up to $75M of registered Encysive stock over 18 months, at a discount to the market price; Encysive will control the timing and amount of any sales (10/20) |
Evolutec |
Private placement of stock |
2.359S |
£2.8 ($5.3) |
Existing investors purchased the stock at 118 pence per share (10/26) |
Idera |
Private placement of stock |
0.781S |
$4 |
Shares were sold at $5.12 to Biotech Shares Ltd. under an equity financing agreement they entered in March; Idera can draw down another $2.25M through 2006 (10/24) |
Innate Pharma |
Private placement of stock |
1.1S |
€5 ($6.4) |
Novo Nordisk A/S invested €5M concurrent with Innate's initial public offering, increasing its stake in Innate to 20% from 18.4% (10/31) |
Insert |
Private placement of stock and warrants |
10S and 4W |
$10 |
Units sold at $1 each consist of a share of Series C-2 preferred stock and 40% warrant coverage to purchase Series D preferred shares at $1.25 each; Arrowhead invested $5M in the deal, and owns 64.5% of Insert (10/26) |
Iomai Corp. |
Private placement of stock |
2.283S |
$10 |
Essex Woodlands Health Ventures and New Enterprise Associates are purchasing the shares at $4.38 each (10/23) |
Lev |
Private placement of stock and warrants |
32.3S and 9.69W |
$21 |
Shares were sold at $0.65 each; the five-year warrants are exercisable at $0.84 per share; placement agent Rodman & Renshaw LLC got another 1.7M warrants as part of the deal, on the same terms (10/23) |
Lexicon |
Private placement of stock |
10.58S |
$40 |
The shares are being sold at $3.78 each; Banc of America Securities LLC was lead placement agent; Lazard Capital Markets LLC was co-agent (10/23) |
Memory |
Private placement of stock and warrants |
28.2S and 7.1W |
$32.2 |
Great Point Partners, MPM Capital and other investors purchased the stock at $1.11 per share; the five-year warrants, purchased for $0.125 each, are exercisable at $1.33 per share (10/5) |
Monogram |
Credit line |
N/A |
N/A |
Merrill Lynch Capital provided a line of credit of up to $10M; the agreement expires in March 2010 (10/3) |
NeuroSearch |
Rights issue |
3.97S |
DKK397 ($68) |
Shares were sold at DKK100 each in the rights offering; Danske Markets was underwriter for the deal (10/19) |
Ondine |
Bought-deal financing |
6.25S |
C$10 |
The shares were purchased by a syndicate led by Canaccord Capital Corp. and including Desjardins Securities Inc. and Pacific International Securities Inc.; they have an overallotment option to purchase up to 937, 500 additional shares (10/20) |
Pharmacopeia |
Private placement of stock and warrants |
5.8S and 1.45W |
$25 |
Shares were sold at the Oct. 12 closing price of $4.28 per share; the five-year warrants are exercisable at $5.14 per share; CIBC World Markets Corp. was lead underwriter; Merriman Curhan Ford & Co. was co-manager (10/13) |
Phylogica Ltd. |
Private placement and share purchase plan |
12.93S |
A$3.75 ($2.8) |
Shares were sold at A$0.29 each, a 20% discount to the five-day average; Cygnet Capital partially underwrote the deal (10/20) |
Poniard |
Term loan |
N/A |
$15 |
SVB Silicon Valley Bank and Merrill Lynch Capital provided the 42-month loan (10/26) |
Senesco |
Private placement of stock and warrants |
1.986S and 0.993W |
$2.3 |
About $1.5M of the investment was provided by certain company directors; the warrants are exercisable at 110% of the stock purchase price (10/11) |
SIGA |
Private placement of stock and warrants |
2S and 1W |
$9.1 |
The shares are being sold at $4.54 each, and the seven-year warrants are exercisable at $4.99 per share; Empire Financial Group and The Shemano Group were placement agents (10/19) |
Trubion |
Private placement of stock |
0.8S |
$10.4 |
Wyeth purchased the shares at $13 each, concurrent with Trubion's initial public offering of shares at the same price (10/18) |
United |
Private placement of convertible notes |
N/A |
$250 |
The 0.5% notes due in 2011 are convertible into a combination of stock and cash at an initial rate $75.2257 per share; totals include the purchase of a $40M investor overallotment option (10/25) |
Vical Inc. (VICL) |
Registered direct offering |
4.98S |
$25 |
An investment fund of Temasek Holdings Ltd. is purchasing the registered stock at $5.02 per share (10/19) |
Vical Inc. |
Registered direct offering |
2.5S |
$12.5 |
The shares were sold from a shelf registration at the Oct. 13 closing price of $5.02 per share; no discounts or commissions were paid (10/16) |
VioQuest |
Private placement of stock and warrants |
7.9S and 2.8W |
$3.95 |
The shares were sold at $0.50 each; the five-year warrants are exercisable at $0.73 per share; Paramount BioCapital Inc. was placement agent (10/24) |
Viragen |
Preferred stock sale |
N/A |
$0.77 |
The Series D preferred stock carries a dividend of 24% per year (10/6) |
York Pharma |
Private placement of stock |
3.09S |
£3 ($5.6) |
The shares were sold to institutional investors at 97 pence each (10/13) |
| Notes: | ||||
| This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. | ||||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. | ||||
| Currency conversions are based on exchange rates at the time of the deal. | ||||
| N/A = Not applicable; ND = Not disclosed. | ||||
| AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.